Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia

Eradication of residual disease is an important endpoint in patients with chronic lymphocytic leukemia (CLL), as it prolongs remission duration after chemoimmunotherapy. We conducted a phase 2 study to evaluate the efficacy and toxicity of lenalidomide given as consolidation therapy in patients with CLL who had residual disease after chemoimmunotherapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Paolo Strati, Michael Keating, Jan Burger, Susan O'Brien, William Wierda, Zeev Estrov, Gracy Zacharian, Alessandra Ferrajoli Source Type: research